Sugi Predict

Sugi Predict / Compounds / SCHEMBL82376

SCHEMBL82376

SCHEMBL82376

CC1=C[C@H]2[C@@]3(O)[C@H](C)[C@@H](OC(=O)CCCCCCCCCCCC(C)CC(=O)O)[C@]4(O)[C@@H]([C@@H]3C=C(CO)C[C@]2(O)C1=O)C4(C)C

nearest known ligand 0.64

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
▸ PRKCA P17252 5/20 0.63
▸ PRKCG P05129 5/20 0.63
▸ PRKD3 O94806 4/20 0.63
▸ PRKCB P05771 4/20 0.63
▸ PRKCH P24723 4/20 0.63
▸ PRKCI P41743 4/20 0.63
▸ PRKCE Q02156 4/20 0.63
▸ PRKCQ Q04759 4/20 0.63
▸ PRKCZ Q05513 4/20 0.63
▸ PRKCD Q05655 4/20 0.63
▸ PRKD1 Q15139 4/20 0.63
▸ USP2 O75604 2/20 0.63
▸ TP53 P04637 2/20 0.63
▸ KDM4E B2RXH2 1/20 0.63
▸ ALDH1A1 P00352 1/20 0.63
▸ SMN1; SMN2 Q16637 1/20 0.63
▸ CYP3A4 P08684 1/20 0.63
▸ CYP2C9 P11712 1/20 0.63
▸ TSHR P16473 1/20 0.63
▸ NFKB1 P19838 1/20 0.63

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL1614871 0.91 PRKCA (0.63) PRKCAPRKCGPRKD3PRKCBPRKCH
SCHEMBL8915854 0.88 PRKCA (0.79) PRKCAPRKCGPRKD3PRKCBPRKCH
Phorbol SCHEMBL28207896 0.88 PRKCA (0.51) PRKCAPRKCGPRKD3PRKCBPRKCH
SCHEMBL18399979 0.88 PRKCA (0.79) PRKCAPRKCGPRKD3PRKCBPRKCH
SCHEMBL3516162 0.88 PRKCA (0.79) PRKCAPRKCGPRKD3PRKCBPRKCH
SCHEMBL258513 0.88 PRKCA (0.79) PRKCAPRKCGPRKD3PRKCBPRKCH
SCHEMBL15725680 0.88 PRKCA (0.79) PRKCAPRKCGPRKD3PRKCBPRKCH
SCHEMBL18622646 0.88 PRKCA (0.79) PRKCAPRKCGPRKD3PRKCBPRKCH
SCHEMBL18629158 0.88 PRKCA (0.79) PRKCAPRKCGPRKD3PRKCBPRKCH
SCHEMBL31074956 0.88 PRKCA (0.79) PRKCAPRKCGPRKD3PRKCBPRKCH

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 1263 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-3740487-B1 BENZAMIDE COMPOUNDS AS BCI INHIBITORS FOR THE TREATMENT OF HIV RECURIUM IP HOLDINGS LLC (US) 2025-01-08 — — EP claimed
CN-111801327-B Benzamide compounds 里科瑞尔姆IP控股有限责任公司 2024-02-09 — — CN claimed
US-11813259-B2 Benzamide compounds RECURIUM IP HOLDINGS, LLC (US) 2023-11-14 — — US claimed
WO-2023128733-A1 METHOD FOR EXPANSION CULTURE OF GAMMA-DELTA T CELL 주식회사 이뮤노맥스 2023-07-06 — — WO claimed
US-20220226314-A1 BENZAMIDE COMPOUNDS RECURIUM IP HOLDINGS, LLC 2022-07-21 — — US claimed
US-11344546-B2 Benzamide compounds Recurium IP Holding, LLC (US) 2022-05-31 — — US claimed
US-11198898-B2 Chemical tools for imaging phospholipase D activity CORNELL UNIVERSITY (US) 2021-12-14 — — US claimed
US-20210009543-A1 BENZAMIDE COMPOUNDS ZENO MANAGEMENT, INC. 2021-01-14 — — US claimed
US-20200339605-A1 BENZAMIDE COMPOUNDS ZENO MANAGEMENT, INC. 2020-10-29 — — US claimed
US-20200338071-A1 BENZAMIDE COMPOUNDS ZENO MANAGEMENT, INC. 2020-10-29 — — US claimed
EP-2268272-A2 COMPOUNDS THAT MODULATE NEGATIVE-SENSE, SINGLE-STRANDED RNA VIRUS REPLICATION AND USES THEREOF Mount Sinai School of Medicine of New York University (US) 2011-01-05 — — EP claimed
WO-2010078461-A1 PROTEIN HYDROLYSATE COMPOSITIONS HAVING ENHANCED CCK RELEASING ABILITY SOLAE, LLC (US) 2010-07-08 — — WO claimed
US-20080260650-A1 Methods of Detection and Therapy of Inflamed Tissues Using Immune Modulation THE GENERAL HOSPITAL CORPORATION (US) 2008-10-23 — — US claimed
US-20080193376-A1 Methods of Enhanced Detection and Therapy of Inflamed Tissues Using Immune Modulation THE GENERAL HOSPITAL CORPORATION (US) 2008-08-14 — — US claimed
WO-2006049599-A1 METHODS OF DETECTION AND THERAPY FOR ATHEROMATOUS PLAQUES USING IMMUNE MODULATION THE GENERAL HOSPITAL CORPORATION (US) 2006-05-11 — — WO claimed
WO-2006050058-A2 METHODS OF DETECTION AND THERAPY OF INFLAMED TISSUES USING IMMUNE MODULATION THE GENERAL HOSPITAL CORPORATION (US) 2006-05-11 — — WO claimed
EP-1290160-B1 HUMAN PELLINO POLYPEPTIDES IMMUNEX CORP (US) 2006-03-29 — — EP claimed
EP-0966523-A1 METHOD FOR THE PRODUCTION OF SELECTED LYMPHOCYTES HEMOSOL INC. (CA) 1999-12-29 — — EP claimed
WO-1998033891-A1 METHOD FOR THE PRODUCTION OF SELECTED LYMPHOCYTES HEMOSOL INC. (CA) 1998-08-06 — — WO claimed
WO-1988005083-A1 METHOD OF INDUCIBLE GENE EXPRESSION WHITEHEAD INSTITUTE FOR BIOMEDICAL RESEARCH (US) 1988-07-14 — — WO claimed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (7 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-11813259-B2 Benzamide compounds MKI67, TMBIM6, HDAC1 PRKCA 4216/4885PRKCG 4549/4885PRKD3 4497/4885
US-11198898-B2 Chemical tools for imaging phospholipase D activity PLD1, PLD2, PLD4 PRKCA 647/4885PRKCG 402/4885PRKD3 264/4885
US-20220226314-A1 BENZAMIDE COMPOUNDS MKI67, TMBIM6, HDAC1 PRKCA 4216/4885PRKCG 4549/4885PRKD3 4497/4885
US-20210009543-A1 BENZAMIDE COMPOUNDS MKI67, TMBIM6, HDAC1 PRKCA 4216/4885PRKCG 4549/4885PRKD3 4497/4885
US-20200339605-A1 BENZAMIDE COMPOUNDS MKI67, TMBIM6, HDAC1 PRKCA 4216/4885PRKCG 4549/4885PRKD3 4497/4885
US-20200338071-A1 BENZAMIDE COMPOUNDS MKI67, TMBIM6, HDAC1 PRKCA 4216/4885PRKCG 4549/4885PRKD3 4497/4885
US-11344546-B2 Benzamide compounds MKI67, TMBIM6, HDAC1 PRKCA 4216/4885PRKCG 4549/4885PRKD3 4497/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.